These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29056373)

  • 1. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
    Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
    Life Sci; 2017 Dec; 191():166-174. PubMed ID: 29056373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking.
    Kato T; Iwasaki H; Kobayashi H; Miyagawa N; Matsuo A; Hata T; Matsushita M
    Eur J Pharmacol; 2017 Apr; 801():1-8. PubMed ID: 28259713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats.
    Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
    J Vet Med Sci; 2018 Mar; 80(3):465-472. PubMed ID: 29375080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.
    Tanimoto A; Ogawa Y; Oki C; Kimoto Y; Nozawa K; Amano W; Noji S; Shiozaki M; Matsuo A; Shinozaki Y; Matsushita M
    Inflamm Res; 2015 Jan; 64(1):41-51. PubMed ID: 25387665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
    Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
    J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
    J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
    Zhang Z; Cao C; Sun S; Xu Q
    Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
    Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
    PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
    Chang BY; Huang MM; Francesco M; Chen J; Sokolove J; Magadala P; Robinson WH; Buggy JJ
    Arthritis Res Ther; 2011 Jul; 13(4):R115. PubMed ID: 21752263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
    Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
    J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats.
    Matsushita M; Masaki M; Yagi Y; Tanaka T; Wakitani K
    Inflamm Res; 1997 Nov; 46(11):461-6. PubMed ID: 9427067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor.
    Uesato N; Miyagawa N; Inagaki K; Kakefuda R; Kitagawa Y; Matsuo Y; Yamaguchi T; Hata T; Ikegashira K; Matsushita M
    Biol Pharm Bull; 2020; 43(2):325-333. PubMed ID: 32009119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction.
    Moy LY; Jia Y; Caniga M; Lieber G; Gil M; Fernandez X; Sirkowski E; Miller R; Alexander JP; Lee HH; Shin JD; Ellis JM; Chen H; Wilhelm A; Yu H; Vincent S; Chapman RW; Kelly N; Hickey E; Abraham WM; Northrup A; Miller T; Houshyar H; Crackower MA
    Am J Respir Cell Mol Biol; 2013 Dec; 49(6):1085-92. PubMed ID: 23889698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
    Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
    Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.
    Novikov FN; Panova MV; Titov IY; Stroylov VS; Stroganov OV; Chilov GG
    Sci Rep; 2021 Nov; 11(1):23120. PubMed ID: 34848799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
    Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.